Options for Treatment of Primary Biliary Cirrhosis

@article{Oo2012OptionsFT,
  title={Options for Treatment of Primary Biliary Cirrhosis},
  author={Ye Htun Oo and James Neuberger},
  journal={Drugs},
  year={2012},
  volume={64},
  pages={2261-2271}
}
Primary biliary cirrhosis (PBC) is a chronic progressive cholestatic disease where there is progressive, granulomatous destruction of the middle-sized bile ducts. The disease affects mainly middle-aged women. The association with other autoimmune diseases and the widespread disturbance of the humoral and cellular immune systems has led to the inclusion of PBC as an autoimmune disease. However, there are several lines of evidence that suggest that both host and environmental factors are… 
9 Citations
Primary biliary cholangitis: a comprehensive overview
TLDR
Serologically, PBC is characterized by presence of antimitochondrial antibodies, which are present in 90–95 % of patients and are often detectable years before clinical signs appear.
Combination antiretroviral studies for patients with primary biliary cirrhosis.
TLDR
It is clear that better tolerated regimens of antiretroviral treatment will be required in future clinical trials, as a double blind, multi-center randomized controlled trial using lamivudine with zidovudine for 6 mo confirmed a significant reduction in alkaline phosphatase, ALT and AST in patients on antiviral therapy.
Sex-related factors in autoimmune liver diseases
TLDR
The recent findings on the influence of sex-dependent mechanisms, which may contribute to differences in presentation, clinical characteristics, disease course, and complications observed between female and male patients with autoimmune liver disease, are discussed.
The Next Frontier of Regulatory T Cells: Promising Immunotherapy for Autoimmune Diseases and Organ Transplantations
TLDR
Recent advances in GMP-grade Tregs isolation and antigen-specific chimeric antigen receptor (CAR)-Tregs development will allow functionally superior cells to migrate to the target organ and may be a promising option for patients with autoimmune diseases and organ transplantations in near future.
Il naltrexone nel trattamento del prurito
TLDR
The authors present the preliminary results of a clinical study on the use of naltrexone in patients with chronic pruritus due to skin diseases, which shows that the degranulation of basophils and mastocytes and histamine release which are caused by morphine, are inhibited by nALTrexone.
Asociación de dos enfermedades granulomatosas raras
TLDR
La sarcoidosis en una enfermedad granulomatosa multisistémica, que afecta a adultos de edad media, con una mayor proporción en mujeres y en ciertos grupos étnicos, y una fibrobroncoscopia que no detectó alteraciones en el árbol bronquial.
Primaari biliaari kirroosi -potilaiden hammashoito
TLDR
Primaarinen biliaarinen kirroosi (Primary Biliary Cirrhosis) on krooninen kolestaattinen maksasairaus, etta sairauden kehittymiseen voisi hyvinkin liittya myos muita kuin immunopatologisia prosesseja, joka on ollut lahtokohtana laajoille tutkimuksille.
Pruritus in connective tissue and other common systemic disease states.
TLDR
Important new areas of treatment target the central and peripheral mechanisms of pruritus and include anticonvulsants, antidepressants, opioid antagonists, and phototherapy.

References

SHOWING 1-10 OF 110 REFERENCES
Management of primary biliary cirrhosis
TLDR
The hydrophilic bile acid, ursodeoxycholic acid (UDCA), has been shown when given in a dose of 13 to 15 mg/kg daily for up to 4 years to delay the time to liver transplantation or death and causes a significant improvement of all the biochemical markers of cholestasis but has no beneficial effects on any of the symptoms or associated disorders.
Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines.
TLDR
The hydrophilic bile acid, ursodeoxycholic acid (UDCA), has been shown when given in a dose of 13 to 15 mg/kg daily for up to 4 years to delay the time to liver transplantation or death and causes a significant improvement of all the biochemical markers of cholestasis but has no beneficial effects on any of the symptoms or associated disorders.
Primary biliary cirrhosis
TLDR
The most specific feature differentiating primary biliary cirrhosis from other causes of intrahepatic cholestasis is demonstration of antimitochondrial antibodies and the typical histology.
Primary biliary cirrhosis: New thoughts on pathophysiology and treatment
TLDR
A multicenter controlled trial is being established to determine whether patients with PBC derive significant benefit from this new line of investigation and management, after cloned a retroviral sequence directly from biliary epithelium extracted from PBC livers.
Natural history of primary biliary cirrhosis.
TLDR
Overall survival of asymptomatic PBC is shorter than for an age- and gender-matched control population, but the patients remaining asymPTomatic had a survival equal to that of the general population.
Novel therapeutic approach to primary biliary cirrhosis patients: anti-eosinophil strategy.
TLDR
Given its efficacy and the absence of side effects, planlukast appears to be the medical treatment of choice for patients with early-stage PBC, but, a randomised, controlled, double-blind trial is urgently needed.
Combination therapy with mycophenolate mofetil and ursodeoxycholic acid for primary biliary cirrhosis.
TLDR
Mycophenolate mofetil (MMF) mediates immunosuppression by selectively and reversibly inhibiting lymphocyte function, and has a more acceptable safety profile than other Immunosuppressants that have been used in the treatment of this disease.
Long‐term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis
TLDR
In conclusion, long‐term UDCA therapy appeared to delay the development of cirrhosis in PBC.
Methotrexate improves biochemical tests in patients with primary biliary cirrhosis who respond incompletely to ursodiol.
TLDR
Addition of methotrexate to a regimen of UDCA and colchicine may be beneficial for patients with PBC who respond incompletely to treatment with UDCA alone or in combination.
Tamoxifen: a novel treatment for primary biliary cirrhosis?
TLDR
Two patients with PBC who show a fall in serum alkaline phosphates levels whilst receiving tamoxifen therapy are reported, which warrants further study.
...
1
2
3
4
5
...